TP53 and B-cell chronic lymphocytic leukemia: Thus, it is still unclear if CK is indeed an independent predictor for patients treated with chemo(immune)therapy or the reported effect of CK is the result of a joint impact of CK and other unfavorable biomarkers, namely TP53 aberrations and U-CLL.